The Latest Cardiac and Vascular News
ELK GROVE VILLAGE, Ill., Feb. 16, 2021 /PRNewswire/ — Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected by Regeneron Pharmaceuticals, Inc. as the exclusive specialty pharmacy partner for EvkeezaTM (evinacumab-dgnb). Evkeeza is approved by the U.S. Food and Drug Administration (FDA) as an adjunct […]
BioSerenity acquires Cardioskin™ global distribution rights PARIS and ATLANTA, Feb. 16, 2021 /PRNewswire/ — WeHealth™ Digital Medicine (e-health division of the Servier Group) and BioSerenity announced today that BioSerenity gains global distribution rights for Cardioskin™, the first WeHealth™ digital Solution co-developped with a start-up, to accelerate the commercialization of Cardioskin™. After successfully collaborating to develop the Cardioskin™, the […]
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3 Expanded indication enables potential treatment of more adults with […]
The favorable opinion of the CPP (French ethic committee) and authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) allow the operational launch of the HEART study. The HEART study will be conducted under the scientific expertise of Jean-Marie Bard, Professor and Hospital Practitioner […]
New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy CAMBRIDGE, MA, February 10, 2021 / B3C newswire / — Thrombolytic Science, LLC (TSI) today announced the granting of three new patents during the last 12 months. The invention relates to methods and compositions for safe and effective thrombolysis for ischemic […]
SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion for CanGaroo® with antibiotics, the next generation of the Company’s CanGaroo […]
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in subjects with stable heart failure with reduced ejection fraction (HFrEF) Antonio Abbate MD PhD, the Principal Investigator, is Professor of Medicine and Medical Director of the Clinical Research Unit at […]
TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ — Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C) In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced LDL-C by nearly half at 24 […]
First enrollment in the study expected in Q1 2021 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today provides […]
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Europe has been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). Professor Nicolas Van […]
